Nanomedicines have emerged as a potential strategy to reduce the toxic effect of drugs administered via conventional approaches. Nanomedicines undergo passive and active targeting of the
tumor tissues, thereby causing localized
drug delivery and reducing
drug demand and side effects. Here, we prepared reduction-sensitive
oxaliplatin-conjugated
human serum albumin nanoparticles with a small size, uniform surfaces, and a satisfactory encapsulation coefficient. The findings of cellular studies demonstrate that utilizing
human serum albumin is effective for active
tumor targeting. The presence of
glutathione-sensitive
disulfide linkers in the crosslinking agent and between Pt(IV) and HSA provided dual reduction sensitivity. Cytotoxicity and cell death were enhanced compared to free
Oxaliplatin. The outcomes demonstrate that the approach maximized
Oxaliplatin's ability to control
tumor growth, induced apoptosis, and reduced drug resistance. Therefore, for the first time, our results imply that OXA-SS-HSA NPs were biocompatible, smart, and effective anticancer nanomedicine for
triple-negative breast cancer therapy.